IL311952A - Antibody or fragment thereof binding specifically to mertk, and anti-tumor agent - Google Patents

Antibody or fragment thereof binding specifically to mertk, and anti-tumor agent

Info

Publication number
IL311952A
IL311952A IL311952A IL31195224A IL311952A IL 311952 A IL311952 A IL 311952A IL 311952 A IL311952 A IL 311952A IL 31195224 A IL31195224 A IL 31195224A IL 311952 A IL311952 A IL 311952A
Authority
IL
Israel
Prior art keywords
seq
amino acid
acid sequence
antibody
sequence given
Prior art date
Application number
IL311952A
Other languages
English (en)
Hebrew (he)
Original Assignee
Chiome Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiome Bioscience Inc filed Critical Chiome Bioscience Inc
Publication of IL311952A publication Critical patent/IL311952A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL311952A 2021-10-15 2022-09-16 Antibody or fragment thereof binding specifically to mertk, and anti-tumor agent IL311952A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021169289 2021-10-15
PCT/JP2022/034801 WO2023063026A1 (ja) 2021-10-15 2022-09-16 ＭｅｒＴＫに特異的に結合する抗体又はその断片、及び抗腫瘍剤

Publications (1)

Publication Number Publication Date
IL311952A true IL311952A (en) 2024-06-01

Family

ID=85987671

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311952A IL311952A (en) 2021-10-15 2022-09-16 Antibody or fragment thereof binding specifically to mertk, and anti-tumor agent

Country Status (9)

Country Link
US (1) US20250326862A1 (https=)
EP (1) EP4417625A4 (https=)
JP (1) JPWO2023063026A1 (https=)
KR (1) KR20240082341A (https=)
CN (1) CN118215684A (https=)
AU (1) AU2022368026A1 (https=)
CA (1) CA3233968A1 (https=)
IL (1) IL311952A (https=)
WO (1) WO2023063026A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7211703B2 (ja) * 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用
WO2020076799A1 (en) * 2018-10-09 2020-04-16 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
BR112021020867A2 (pt) * 2019-04-19 2022-01-04 Genentech Inc Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
JP2023506465A (ja) * 2019-12-13 2023-02-16 アレクトル エルエルシー 抗ＭｅｒＴＫ抗体及びその使用方法

Also Published As

Publication number Publication date
CN118215684A (zh) 2024-06-18
EP4417625A1 (en) 2024-08-21
EP4417625A4 (en) 2026-01-14
CA3233968A1 (en) 2023-04-20
WO2023063026A1 (ja) 2023-04-20
JPWO2023063026A1 (https=) 2023-04-20
US20250326862A1 (en) 2025-10-23
AU2022368026A1 (en) 2024-05-02
KR20240082341A (ko) 2024-06-10

Similar Documents

Publication Publication Date Title
IL284258B2 (en) Anti-pd1 antibodies and their use as therapeutics and diagnostics
IL322472A (en) Humanized antibodies against c-kit
IL264970B1 (en) ANTI-TIM-3 antibodies and their use
IL290959B2 (en) Preparations containing antibody-drug conjugates and methods for their production
IL292959A (en) Biparatropic antibodies of cd73
IL300764A (en) Antibody and composition of calr-cd3 mutant anti-clotting drugs
IL267567B2 (en) Anti-cd3 antibody for use in the treatment or prophylaxis of cancer, and molecules containing said antibody
IL277354B2 (en) Methods and compounds for downregulating soluble CD28 receptor
IL270308B2 (en) Anti-interferon gamma antibodies and their uses
IL294218A (en) Antibody against cdcp1
IL307533B2 (en) Anti-ccr8 antibodies
IL250848B (en) Cancer cell-specific antibody, anti-cancer drug and cancer diagnosis method
IL298867A (en) Bispecific immune cell engagers with binding specificity for hla-g and another antigen
IL296514A (en) Bispecific antibody
IL267340B2 (en) Anti-pcna monoclonal antibodies and use thereof
IL302544A (en) Anti-TSPAN8-anti-CD3 bispecific antibody and anti-TSPAN8 antibody
IL318237A (en) A therapeutic binding molecule that binds to CCR9
IL318087A (en) Antibody against human TRL7
IL320488A (en) Anti-cd16a antibody and application thereof
IL310700A (en) Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
IL311952A (en) Antibody or fragment thereof binding specifically to mertk, and anti-tumor agent
IL299931B1 (en) Anti-pvrig protein antibody or antibody fragment and use thereof
IL300166A (en) Methods for using a PD-1 X CTLA-4 bispecific molecule
IL319909A (en) Bispecific antibody and its use
IL320593A (en) Anti-CD25 antibody and anti-CD25 antibody conjugate